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DISSOLUTION TESTING OF PREDNISONE AND SALICYLIC ACID 




Dissolution testing is routinely carried out in the pharmaceutical industry to determine the 
rate of dissolution of solid dosage forms. This test is one of the several tests that 
pharmaceutical companies typically conduct on oral dosage formulations (e.g., tablets) to 
determine compliance. The USP Dissolution Testing Apparatus 2 is the most common of 
the apparatuses listed in the USP.  However, it has been shown previously that the 
dissolution profile of a tablet undergoing dissolution in the USP Dissolution Apparatus 2 
can be affected by the tablet location in the apparatus.  
In this work, the dissolution rates of both non-disintegrating tablets (salicylic 
acid) and disintegrating tablets (Prednisone) were experimentally determined for many 
different tablet locations, both centered on the vessel bottom and off-center.  The location 
of the tablet was experimentally varied in very small increments in order to determine the 
exact location where a transition in the dissolution profile occurred.  It was found that in 
a small region (2-4 mm in radius) centered around the vessel centerline just below the 
impeller the dissolution profiles were similar to those observed with a centered tablet.  
However, outside this region the dissolution profiles were found to be significantly 
different, as indicated by the values of the Similarity Factor f1 and the Difference Factor 
f2.  These finding are consistent with previous hydrodynamic investigations that showed 
the existence of a poorly mixed zone below the USP Apparatus 2 impeller.  The results of 
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Dissolution testing is routinely carried out in the pharmaceutical industry to determine the 
rate of dissolution of solid dosage forms. In addition to being routinely used by 
pharmaceutical companies to demonstrate adequate drug release in vivo (through in 
vivo/in vitro (IVIVC) correlation), in vitro dissolution testing is used to assist with 
formulation design, process development, and especially the demonstration of batch-to 
batch reproducibility in production. Dissolution testing is one of the several tests that 
pharmaceutical companies typically conduct on oral dosage formulations (e.g., tablets) to 
determine compliance and to release products for distribution and sales. 
Although the USP lists several different dissolution test apparatuses (USP, 2008), 
most dissolution tests are currently conducted with USP Dissolution Test Apparatuses 1 
and 2. The USP Dissolution Apparatus 2 is the most commonly and widely used 
apparatus specified by the USP, and it is the focus of the study presented in this work. 
The dimensions, characteristics, and operating conditions of USP Dissolution Apparatus 
2 are detailed by the USP and all users must conform to these prescriptions when 
conducting dissolution tests. The USP Dissolution Apparatus 2 comprises a glass vessel 
and an agitation system. The glass vessel is a cylindrical glass tank with a semispherical 
bottom, and a working volume of either 500 mL or 900 mL (Figure 1.1). The agitation 
system consists of a two-blade paddle impeller mounted on a shaft centrally located in the 






Figure 1.1 USP Dissolution Apparatus 2: paddle impeller and glass vessel. 
In the industrial practice, replicate dissolution tests are typically conducted in 
parallel using commercially available systems containing six or more individual USP 
Dissolution Apparatus 2 units (Figure 1.2). These systems allow the agitation system 
(motor and impellers) to be lifted above the rack holding the vessels, as shown in this 
figure, in order to prepare the system for the actual test. Each vessel is filled with a 
prescribed amount of a fluid simulating gastric or intestinal fluids, and maintained at 
constant temperature of 37°C by either a water bath or a heating jacket. The test consists 




inside the vessels, as required by the USP, starting the agitation so that the paddles rotate 
at 50 RPM or 100 RPM, adding a single dosage form unit, such as a tablet, to each vessel 
simultaneously, drawing liquid samples over time from a prescribed location within the 
vessel, analyzing the drug concentration in each sample, and determining the dissolution 
profile over time. These profiles must be within a predefined range, and cannot differ 
significantly from the dissolution profile that the drug manufacturer has initially 
submitted to the FDA when the drug was approved. Any dissolution profile that is found 
to be statistically different, according to a predefined criterion (Moore and Flanner, 
1996), from the reference profile established for that dosage form implies failure of the 
test and non-compliance of the production batch being tested. When this occurs, the batch 
cannot be released for commercialization and it is often disposed of. The cost of such 
failure is often significant given the typical high value of the product.  
 







The USP Dissolution Apparatus 2 has been used in the pharmaceutical industry for 
decades, since this test was first officially introduced almost 30 years ago (Cohen et al. 
1990). Nevertheless, and despite its widespread use in the industry, dissolution testing 
remains susceptible to significant error and test failures. A review of the literature shows 
testing systems containing seven Apparatus 2 units (Distek 5100 bathless dissolution 
apparatus). that there have been numerous reports describing high variability of test 
results (Manger et al. 2003, Moore et al. 1995, Qureshi and McGilveray, 1999, Qureshi 
and Shabnam, 2001, Costa and Lobo, 2001, Bocanegra et al. 1990, Cox and Furman, 
1982, Cox et al. 1983) even when the so called "calibrator tablets" (i.e., tablets 
manufactured for the sole purpose of testing the proper operation of the dissolution test 
equipment) are used (Moore et al. 1995, Qureshi and Shabńam, 2001, Cox and Furman, 
1982, Kukura et al. 2003, Baxter et al. 2005) Failures linked to dissolution testing 
resulted in 47 product recalls during the period 2000-2002, representing 16% of non-
manufacturing recalls for oral solid dosage forms (FDC Reports, 2001, FDC Reports, 
2002, FDC Reports, 2003)Irrespective of the underlying causes (such as incorrect use of 
the equipment or deviation of dissolution profile from the standard caused by incorrect 
tablet formulation) failed dissolution tests can result in product recalls, costly 
investigations, potential production delays, which, in turn, can have a significantly 
negative financial impact. Some of the same studies have indicated that the 




 reproducibility of dissolution testing data and the inconsistency of dissolution results. 
This is hardly surprising considering that the USP Dissolution Apparatus 2 is a small, 
unbaffled vessel with a hemispherical bottom provided with a slowly rotating paddle, in 
which a tablet (or another dosage form) is dropped. This system is associated with a 
complex hydrodynamics resulting in fluid velocities whose directions and intensities are 
highly dependent on the location within the vessel (Bai and Armenante, 2008). To 
complicate the issue farther, tablets have often been reported to land at different locations 
at the bottom of the vessel after they are dropped in the vessel at the beginning of a test, 
making the dissolution process even more susceptible to hydrodynamic factors. Until 
recently, limited information has been available on the hydrodynamics of the dissolution 
apparatus and the effects of operating and geometric variables on the velocity distribution 
in the system. Such information is critical to advance the fundamental understanding of 
the dissolution rate process, enhance the reliability of dissolution testing, and eliminate 
artifacts associated with test methods, especially since dissolution measurements have 
often been reported to be inconsistent and poorly reproducible. Only a few researchers 
(Kukura et al. 2004, Baxter et al. 2005, Bai and Armenante, 2008) have conducted 
dissolution test in which drug tablets were fixed at different locations along the bottom of 





OBJECTIVE OF THIS WORK 
 
The literature review presented in the previous chapter shows that our current knowledge 
of the dissolution testing systems is still incomplete, and that there is a need for 
conducting work aimed at understanding the impact of a number of operating variables.  
In particular, although it is now known that the location of the tablet on the vessel bottom 
can, in general, affect the dissolution profiles, especially if the location is significantly 
different from that of a centered tablet, it still remains to be determined whether small 
changes in tablet location can still affect the results of dissolution test, as it had been 
hypothesized in the literature (Ge and Armenante, 2008). 
Therefore, the overall goal of this research work is to conduct dissolution testing 
experiments with disintegrating and non-disintegrating calibrator tablets (10-mg 
Prednisone tablets and 300-mg salicylic acid tablets) in order to determine precisely the 
effect of tablet location on dissolution profiles, especially when the tablet location is 
varied in small increments. The achievement of this objective can help the dissolution 
testing practitioners understand whether it is prudent to discard the results of a dissolution 
test even before the test is completed, based on the initial position of the tablet after it has 







EXPERIMENTAL APPARATUS, MATERIALS, AND METHOD 
 
4.1 Dissolution Vessel and Agitation System 
All dissolution experiments were conducted using a Distek 5100 Bathless Dissolution 
Apparatus 2 (Distek Inc., North Brunswick, NJ),  capable of operating seven dissolution 
vessels at a time.  An Apparatus 2 vessel consisting of an unbaffled, cylindrical, 
transparent, glass tank with hemispherical bottom, and internal diameter, T, equal to 
100.16 mm and overall capacity of 1 L was used as the dissolution vessel.  The agitation 
system consisted of a standard USP 2 two-blade paddle impeller mounted on a shaft and 
connected to the motor in the Distek system. The exact geometry of each component of 
the impeller was obtained by measuring the actual dimensions with a caliper, which were 
found to be as follows: shaft diameter, 9.53 mm; length of the top edge of the blade, 
74.10 mm; length of the bottom edge of the blade, 42.00 mm; height of the blade, 19.00 
mm; and thickness of the blade, 5.00 mm. The impeller clearance off the vessel bottom 
was 25 mm, as specified by the USP (2008).  When the vessel was filled with 500 mL of 
dissolution media, the corresponding liquid height, H, as measured from the bottom of 
the vessel, was 78.6 mm. When the vessel was filled with 900 mL of dissolution media, 
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4.2 Experimental Materials 
Dissolution studies were conducted using both disintegrating and non-disintegrating solid 
oral dosage forms, i.e., respectively, 10-mg Prednisone calibrator tablets (disintegrating 
tablets, NCDA #2), kindly provided by Dr. Zongming Gao (Food and Drug 
Administration (FDA), Division of Pharmaceutical Analysis, Center for Drug Evaluation 
and Research, St. Louis, MO), and 300-mg salicylic acid calibrator tablets (non-
disintegrating tablets; USP Lot Q0D200), purchased from USP, Rockville, MD.  The 
dimensions of the tablets were measured using a caliper.  Their diameters were found to 
be 7.80 mm for Prednisone tablets and 9.52 mm for salicylic acid tablets. Their 
corresponding thicknesses were 3.76 mm and 4.4 mm, respectively.  A commercial 
acrylic glue was used to fix the tablet at a particular location on the bottom of the 
dissolution vessel. 
The dissolution medium for Prednisone tablets consisted of de-aerated distilled 
water.  The dissolution medium for salicylic acid tablets consisted of a de-aerated 0.05 M 
monobasic potassium phosphate buffer solution to which an NaOH solution (50% (w/w) 
concentration) was added to reach a final pH value of 7.4. 
All media were de-gassed in the de-gassing apparatus shown in Figure 4.2 
following the USP General Test Chapter on DISSOLUTION <711>, based on to the 
degassing method developed by Moore (Moore, 1996).  Accordingly, the medium was 
placed in carboy tank, which was then connected to a vacuum pump.  Vacuum was 





were used as needed, i.e., in 500 mL aliquots for the experiments with Prednisone tablets 
and 900 mL aliquots for the experiments with salicylic acid tablets. 
Disposable PVDF 0.45 m filters were during sampling to remove possible solid 
particles that could have entered the sample prior to sample analysis as described below. 
 
Figure 4.2 Equipment used to de-aerate the dissolution medium. 
 
4.3 Experimental Method 
The experimental procedure used in this work was slightly different from that typically 
used in dissolution testing (USP, 2008) since the tablet was not dropped in the stirred 
dissolution medium but was glued in place with a minute amount of glue prior to the 
addition of the dissolution medium and the beginning of the experiment. 
Before each experiment, all key geometrical measurements were checked 
(impeller clearance, impeller position, etc.). In order to test the effect of tablet location 
during dissolution testing, a tablet was attached at one of eight predefined points on the 
vessel bottom with a very small bead of commercial glue.  The locations of the tablets on 





the vessel bottom.  Off-center tablets were placed so that their center was at one of seven 
off-center locations on the vessel bottom, 2°, 4°, 6°, 8°, 10°, 15° or 20° away from the 
vessel vertical centerline.  This angle originated from the center of the sphere comprising 
the hemispherical vessel bottom, and was measured starting from the vertical centerline 
to the point of interest, (e.g., the angle would be zero for the central point below the 
impeller).  Additional details of the experimental operating conditions are presented in 
Table 4.1.   
Once the tablet and the vessel were setup properly, the de-aerated dissolution 
medium (500 mL of distilled water for Prednisone or 900 mL of buffer medium for 
salicylic acid), previously preheated at 37.5 
o
C, was gently poured into the vessel in order 
to minimize the introduction of gas and prevent the rapid initial dissolution of the tablet.  
Because of the thermal inertia of the vessel, the resulting temperature of the liquid was  
37 
o
C.  This temperature was maintained throughout the dissolution experiment by the 
system’s temperature controller.  Agitation was started immediately after the addition of 
the dissolution medium.  The agitation speed was 50 rpm for Prednisone tablets and 100 
rpm for salicylic acid tablets, respectively (USP, 2008).  The first sample was taken 
immediately after agitation was started. This data was defined as zero-time point. The 
time interval between samples was 5 minutes. Each experiment lasted 45 minutes and a 
total of 10 samples were taken for each experiment.  Experiments were performed in 





































































































































Figure 4.3 Top Panel: side view of the bottom portion of the USP Apparatus 2 showing 
the different locations of a tablet center during dissolution experiments (only centered, 
10°, and 20° tablets are shown); Bottom Panel: top view of a smaller section of the 









Table 4.1 Operation Conditions for Dissolution Experiments. 
Dose 10 mg (Prednisone tablets) 
500 mg (Salicylic acid tablets) 
Medium 500 mL of de-aerated, distilled water 
(Prednisone tablets) 
 




Agitation Speed 50 rpm (Prednisone tablets) 
100 rpm (Salicylic acid tablets) 
Filter PVDF 0.45um 
UV Wavelength in spectrophotometer) 242 nm (Prednisone tablets) 
296 nm (Salicylic Acid tablets) 
Standard Tablets Calibrated tablets 
Sampling time 5-minute intervals; 45 minutes total 
 
Sampling consisted of removing a 10-mL medium aliquot with a 10-mL syringe 
connected to a cannula (2 mm ID). The volume of medium removed by sampling was not 
replaced, in accordance to the USP procedure (2008).  The sampling point was 
horizontally located midway between the impeller shaft and the vessel wall, and midway 
between the top edge of the impeller and the surface of the dissolution medium, i.e., 
within the sampling zone prescribed by the USP.  After sample withdrawal, about 2-mL 
of the sample were discarded, the cannula was removed, and a PVDF 0.45 m filter was 
mounted on the syringe. The remaining sample volume (about 8-mL) was transferred to a 





Analysis of samples was carried out using 1-cm quartz cells filled with the 
solution and placed in a UV-visible spectrophotometer (Varian CARY 50 Bio) measuring 
absorbance at a specified wavelength, i.e., 242 nm for Prednisone and 296 nm for 
salicylic acid (the approximate wavelengths of maximum absorbance for the respective 
tablets).  Before placing the quartz cell into the UV spectrometer, the cell was rinsed 
three times with the same solution sample. Knowing the calibration curve described 
below, this absorption reading was used to obtain the concentration of dissolved 
Prednisone or salicylic acid in the sample. 
Calibration curves for Prednisone and salicylic acid tablets were obtained. 
Reference standard solutions of each drug were prepared in the dissolution medium and 
diluted to obtain solutions of different known concentrations.  The absorbance of these 
solutions was obtained in order to generate absorbance-vs.-concentration standard curves. 
The calibration curves are presented in Table 4.2 and Figure 4.5.  These results show that 
the calibration curves were always linear (R
2
=0.9974 for Prednisone, and R
2
=0.9999 for 


















Absorption2 Absorption3 Average  Absorption 
 
Concentration (mg/mL) 
0.156 0.155 0.155 0.155333333 0.0033 
0.241 0.242 0.241 0.241333333 0.005 
0.469 0.468 0.467 0.468 0.01 
0.564 0.565 0.563 0.564 0.0125 
0.73 0.729 0.728 0.729 0.0166 
1.012 1.011 1.009 1.010666667 0.025 
2.185 2.182 2.181 2.182666667 0.05 
Absorption1 Absorption2 Absorption3 Average  Absorption Concentration (mg/mL) 
2.321 2.324 2.32 2.321667 0.1 
1.749 1.745 1.746 1.746667 0.075 
0.911 0.91 0.912 0.911 0.0375 
0.464 0.465 0.464 0.464333 0.0187 
0.255 0.254 0.255 0.254667 0.0093 
0.149 0.15 0.149 0.149333 0.0046 
















4.4 Data Analysis 
The dissolution profiles obtained with tablets at off-center locations in the USP 
Apparatus 2 were compared to those obtained with the centrally located tablets in the 
same apparatus in order to determine whether these dissolution curves were statistically 
similar or different.  
The similarity of two dissolution profiles was determined using the FDA-
recommended approach consisting of using a model-independent method based on the 
similarity factor (f1) and difference factor (f2) proposed by Moore and Flanner (Moore 


































                                                                 (4.4.2) 
Where Rt is the reference assay at time t, Τt is the test assay at the same time, and n is the 
number of points. The f1 factor measures the percent error between two curves for all 
points. The percent error is zero when the test and drug reference profiles are identical, 
but increases proportionally with the dissimilarity between the two dissolution profiles. 
The higher the similarity factor f1 (which can be in the range 0 to 100), the higher the 
average difference between reference and test curves is. The f2 factor is a logarithmic 
transformation of the sum-squared error of differences between the test and the reference 
products over all time points (which can be in the range -α to 100).  If this difference is 
higher than 100, normalization of the data is required.  The higher the difference factor f2, 





2001). Public standards have been set by Food and Drug Administration (FDA) for f1 and 
f2. Accordingly, statistical similarity between the two curves being compared requires 








5.1 Results for Dissolution of Prednisone Tablets 
In this section of the study, the dissolution profiles are presented for Prednisone tablets at 
eight different tablet locations (0°, 2°, 4°, 6°, 8°, 10°, 15°, and 20°) at the bottom of the 
dissolution vessel using the Standard USP Dissolution System at an agitation speed of 50 
rpm.  The results are reported in terms of C/C*, i.e., the ratio of the Prednisone 
concentration in the dissolving medium, C, at a given time, t, relative to the final 
concentration, C*, obtained when the entire 10-mg tablet was completely dissolved.  
Figure 5.1 presents these results.  One can see that there is a significant similarity 
between the dissolution profiles for the tablets located at the 0°, 2° and 4° locations. 
However, these profiles are very different from those obtained at tablet locations where 
the angle was equal to, or larger than, 6° off the vertical centerline.  The corresponding f1 
and f2 values quantifying the similarity/difference of the dissolution profiles with respect 
to that for the centrally located tablet are presented in the Table 4.1.  Both f1 and f2 were 
in the required range when the tablets were at the 2° and 4° locations.  When the tablet 
was 6° off center, the f1 value was out of range, whereas the f2 value was in-range, 
although barely above 50.  However, for tablets at locations 6° or above, both the f1 
values and the f2 values were out of the required range to insure statistical similarity, 
which implies that tablets at or above the 6° locations would fail the dissolution test. 





dosage form (Prednisone) depend strongly on tablet location in a standard USP Apparatus 
2 Dissolution System.  These results are in agreement with previously reported work 
from this and other research groups, although the results presented here show a very high 
degree of sensitivity of the dissolution profiles to even small deviations of the tablet 
location from the centered symmetric position.  In other terms, even tablet locations only 
a few degrees (as low as 6°) off center result in dissolution profiles that are statistically 
different from those for the “regular” center-position tablet.  Detailed results are 
presented in Appendix C. 
 
Figure 5.1 Dissolution profiles for Prednisone for eight different tablet positions during 
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4 Degree Off-Center Tablet
6 Degree Off-Center Tablet
8 Degree Off-Center Tablet
10 Degree Off-Center Tablet
15 Degree Off-Center Tablet





Table 5.1 f1 and f2 values for the dissolution profiles of Prednisone tablets at different 
off-center locations compared to that for a centered tablet. 
Tablet off-center angle f1 f2 
2   2.789 88.993 
4   4.614 81.779 
6 25.344 52.286 
8 31.301 47.556 
10 32.575 46.714 
15 35.468 44.607 




5.2 Results for Dissolution of Salicylic Acid Tablets 
In this section of the study, the dissolution profiles are presented for salicylic acid tablets 
at eight different tablet locations (0°, 2°, 4°, 6°, 8°, 10°, 15°, and 20°) at the bottom of the 
dissolution vessel using the Standard USP Dissolution System at an agitation speed of 
100 rpm.  As before, the results are reported in terms of C/C*, i.e., the ratio of salicylic 
acid concentration in the dissolving medium, C, at a given time, t, relative to the final 
concentration, C*, obtained when the entire 300 mg tablet was completely dissolved.  
Figure 5.2 presents these results.  One can see that there is a significant similarity 
between the dissolution profiles for the tablets located at the 0° and 2° locations. 
However, these profiles are very different from those obtained at tablet locations where 
the angle was equal to, or larger than, 4° off the vertical centerline.  The corresponding f1 
and f2 values quantifying the similarity/difference of the dissolution profiles with respect 
to that for the centrally located tablet are presented in the Table 5.2.  Both f1 and f2 were 
in the required range when the tablet was at the 2° location.  However, when the tablets 





(barely) in-range, which still implies that these tablets would fail the dissolution test.  
These results confirm that the dissolution profiles for the chosen disintegrating solid 
dosage form (salicylic acid) depend strongly on tablet location in a standard USP 
Apparatus 2 Dissolution System.  These results are in agreement with previously reported 
work from this and other research groups, although the results presented here show a very 
high degree of sensitivity of the dissolution profiles to even small deviations of the tablet 
location from the centered symmetric position.  In other terms, even tablet locations only 
a few degrees (as low as 4°) off center result in dissolution profiles that are statistically 
different from those for the “regular” center-position tablet.  Detailed results are 
presented in Appendix D. 
 
 
Figure 5.2 Dissolution profiles for salicylic acid for eight different tablet positions during 
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Table 5.2 f1 and f2 values for the dissolution profiles of salicylic acid tablets at different 























Tablet off-center angle f1 f2 
2   0.71756 99.90817 
4 25.92636 73.90919 
6 35.83108 66.75391 
8 36.00753 66.70632 
10 36.23103 66.65084 
15 45.77109 62.17712 







The experimental results presented here clearly demonstrate the importance of tablet 
location during dissolution testing. The experimental dissolution data for both 
disintegrating and non-disintegrating tablets indicate that the location of the tablet 
produces statistically different dissolution testing results. This is in good agreement with 
the previous results of Bai and Armenante (2009), Bai and Armenante, (2007), and 
Baxter et al. (2005). The statistical difference between the results obtained here for 
different tablet locations can be quantified by examining the value of the difference 
factor, f1 , which is always outside the range established by FDA for statistical similarity 
(Table 4.1 and 4.2). The difference factor f2 calculated for the off-center tablets vs. the 
centered tablets produces more ambiguous results, since many of the values reported in 
Table 4.1 and 4.2 for this factor are within the FDA limits (50-100), although always 
borderline. This apparent conflict between the factors recommended by the FDA is 
caused by the fact that f2 is not a very sensitive statistical tool to assess differences among 
dissolution curves. The contradictory outcome of these two factors has also been reported 
by other researchers (Bai and Armenante, 2009, Baxter et al. 2005, Costa. and Lobo, 
2001), who have pointed out that the conflict between the two methods shows that the 
similarity factor f2 may not be very robust for its intended task. While the difference 
between dissolution curves obtained at different tablet locations may make sense for non-
disintegrating, eroding tablets (since the complex hydrodynamics of the Apparatus 2 can 
be expected to produce different flows around tablets at different locations (Bai and 





disintegrating tablets, since the tablet fragments, once the tablet disintegrates, move 
toward the center of the vessel, thus possibly eliminating any further effect of the initial 
tablet location on the remaining portion of the dissolution process. The explanation for 
this apparent contradiction comes from a closer examination of Figure 4.1. This figure 
shows that at t=0 minutes all curves start at the same point, and that the concentration 
ratio C/C* at this time is appreciably high (6%). Within 5 minutes, the curves for the off-
center tablets diverge from those for the centrally located ones. However, after this time 
the two sets of curves remain nearly parallel to each other. One can conclude that what 
happens during the first 5 minutes is critical to promote dissolution and disintegration, 
and that the reminder of the dissolution process simply adds to that initial basis. In fact, it 
was visually observed that by t=5 minutes the off-center tablets were nearly completely 
disintegrated, whereas it took about 8 minutes for the centered tablet to do the same. 
Apparently, the improved hydrodynamics experienced by off-center tablets results in a 
more rapid dissolution and disintegration of the tablet, generating a higher dissolved 
concentration of the drug during the initial phase of the dissolution process. Once this 
initial process is complete and the tablet is fully disintegrated, the dissolution process 
proceeds at a similar rate irrespective of the initial location of the tablet in the vessel. 
The process is different for non-disintegrating tablets. Here, since the tablets 
remain at their initial location during the whole process, the improved hydrodynamics 
experienced by off-center tablets results in their faster dissolution rate throughout the 
entire dissolution test. This can be clearly seen in Figure 4.2, where the gap between the 
curves keeps growing as times goes by (obviously this cannot go on forever, as predicted 





C*<CS, where CS is the saturation concentration). Unlike the disintegrating prednisone 
tablets, the non-disintegrating salicylic acid tablets are subjected to higher dissolution 
rates during the entire test, and not only until disintegration occurs. Although a major 
difference in dissolution performance can be seen between off-center and centered 
tablets, not all off-center tablet positions are equal. A small off-center tablet displacement 
of only 4° is already capable of producing significantly and statistically different 
dissolution results compared to the centered tablet case. One can only speculate on how 
many dissolution tests routinely fail simply as a result of such small random variations in 
the tablet resting position after it has been dropped in the vessel. However, greater off-
center deviations of the tablet location from the centerline can produce even larger 
variations in test results. Both Figure 4.1 and Figure 4.2 show that the dissolution curves 








A number of conclusions can be drawn from this work, as follows: 
1. The dissolution performance of both disintegrating Prednisone tablets and non 
disintegrating salicylic acid tablets in the USP Dissolution Testing Apparatus 2 is 
strongly dependent on tablet position, as previously reported by this and other 
research groups.  Thus, this apparatus is prone to highly variable results which 
may not be associated with the tablets undergoing testing but with the 
hydrodynamic characteristics of the apparatus itself and the location of the tablet 
on the vessel bottom. 
2. In most of the cases reported here with calibrator tablets, displacing and keeping 
the tablet off center often resulted in failing the dissolution test. Test failures 
occurred with both disintegrating and non-disintegrating tablets even when the 
tablets were only slightly displaced from the centered tablet location (≤4° for 
Prednisone tablets and ≤2° for salicylic acid tablets), as indicated by the 
systematic and statistically significant off-specification values of the similarity 
factor f1. In the same experiments, the difference factor f2 was less sensitive to 
detect differences in dissolution profiles, and its value was either off-specification 
or borderline. 
3. Non-disintegrating off-center tablets may fail because the flow fields surrounding 
them are appreciably different from the flow field surrounding a centrally placed 





4. Disintegrating off-center tablets may fail because the initial disintegration and 
dissolution process during the first few minutes of the test is sufficiently different 
between off-center and centered tablets. 
5. These finding are consistent with previous hydrodynamic investigations that 
showed the existence of a poorly mixed zone below the USP Apparatus 2 impeller 
(Ge and Armenante, 2007; Ge and Armenante, 2009).   
6. The results of this work can guide the practitioner on when to accept or discard 



































DISSOLUTION PROFILE OF PREDNISONE TABLETS 
Figure A.1 to A.8 show Dissolution of Prednisone Tablet at different locations. 
 
 













































































































































































DISSOLUTION PROFILE OF SALICYLIC ACID TABLETS 
Figure B.1 to B.8 show Dissolution of Salicylic Acid Tablet at different locations. 
 
Figure B.1 Dissolution profile of Salicylic Acid tablet at Central location. 
 











































































































































This appendix includes all tables of Dissolution Profiles of Prednisone Tablet at different 
tablet locations in detail. 














0 0.053 0.023 -0.00035 0.0012 0.0600 0.0011 6.0023 
5 0.127 0.023 -0.00035 0.0029 0.1438 0.0036 14.3828 
10 0.204 0.023 -0.00035 0.0046 0.2310 0.0034 23.1030 
15 0.254 0.023 -0.00035 0.0058 0.2877 0.0049 28.7655 
20 0.296 0.023 -0.00035 0.0067 0.3352 0.0060 33.5220 
25 0.336 0.023 -0.00035 0.0076 0.3805 0.0051 38.0520 
30 0.383 0.023 -0.00035 0.0087 0.4337 0.0043 43.3748 
35 0.422 0.023 -0.00035 0.0096 0.4779 0.0047 47.7915 
40 0.436 0.023 -0.00035 0.0099 0.4938 0.0040 49.3770 
45 0.446 0.023 -0.00035 0.0101 0.5051 0.0041 50.5095 
 
 















0 0.052 0.023 -0.00035 0.0012 0.0589 0.0013 5.8890 2.7893 88.993 
5 0.156 0.023 -0.00035 0.0035 0.1767 0.0083 17.667 
  10 0.211 0.023 -0.00035 0.0048 0.2390 0.0060 23.895 
  15 0.268 0.023 -0.00035 0.0061 0.3035 0.0094 30.351 
  20 0.31 0.023 -0.00035 0.0070 0.3511 0.0029 35.107 
  25 0.341 0.023 -0.00035 0.0077 0.3862 0.0043 38.618 
  30 0.386 0.023 -0.00035 0.0087 0.4371 0.0024 43.714 
  35 0.429 0.023 -0.00035 0.0097 0.4858 0.0017 48.584 
  40 0.436 0.023 -0.00035 0.0099 0.4938 0.0017 49.377 

























0 0.052 0.023 -0.00035 0.0012 0.0589 0.0017 5.8890 4.6143 81.7799 
5 0.165 0.023 -0.00035 0.0037 0.1869 0.0011 18.6863 
  10 0.202 0.023 -0.00035 0.0046 0.2288 0.0017 22.8765 
  15 0.259 0.023 -0.00035 0.0059 0.2933 0.0035 29.3318 
  20 0.312 0.023 -0.00035 0.0071 0.3533 0.0013 35.3340 
  25 0.365 0.023 -0.00035 0.0083 0.4134 0.0020 41.3363 
  30 0.39 0.023 -0.00035 0.0088 0.4417 0.0020 44.1675 
  35 0.423 0.023 -0.00035 0.0096 0.4790 0.0017 47.9048 
  40 0.446 0.023 -0.00035 0.0101 0.5051 0.0017 50.5095 
  45 0.472 0.023 -0.00035 0.0107 0.5345 0.0024 53.4540 
  
 















0 0.053 0.023 -0.00035 0.0012 0.0600 0.0017 6.0023 25.3444 52.2864 
5 0.206 0.023 -0.00035 0.0047 0.2333 0.0030 23.3295 
  10 0.286 0.023 -0.00035 0.0065 0.3239 0.0024 32.3895 
  15 0.325 0.023 -0.00035 0.0074 0.3681 0.0024 36.8063 
  20 0.408 0.023 -0.00035 0.0092 0.4621 0.0036 46.2060 
  25 0.439 0.023 -0.00035 0.0099 0.4972 0.0057 49.7168 
  30 0.471 0.023 -0.00035 0.0107 0.5334 0.0041 53.3408 
  35 0.487 0.023 -0.00035 0.0110 0.5515 0.0041 55.1528 
  40 0.502 0.023 -0.00035 0.0114 0.5685 0.0036 56.8515 
  45 0.516 0.023 -0.00035 0.0117 0.5844 0.0029 58.4370 
  
 















0 0.053 0.023 -0.00035 0.0012 0.0600 0.0007 6.0023 31.3017 47.5564 
5 0.235 0.023 -0.00035 0.0053 0.2661 0.0017 26.6138 
  10 0.328 0.023 -0.00035 0.0074 0.3715 0.0046 37.1460 
  15 0.394 0.023 -0.00035 0.0089 0.4462 0.0034 44.6205 
  20 0.411 0.023 -0.00035 0.0093 0.4655 0.0007 46.5458 
  25 0.452 0.023 -0.00035 0.0102 0.5119 0.0024 51.1890 
  30 0.468 0.023 -0.00035 0.0106 0.5300 0.0033 53.0010 
  35 0.493 0.023 -0.00035 0.0112 0.5583 0.0017 55.8323 
  40 0.507 0.023 -0.00035 0.0115 0.5742 0.0036 57.4178 






















0 0.055 0.023 -0.00035 0.0012 0.0623 0.0007 6.2288 32.5758 46.7143 
5 0.245 0.023 -0.00035 0.0055 0.2775 0.0036 27.7463 
  10 0.335 0.023 -0.00035 0.0076 0.3794 0.0036 37.9388 
  15 0.39 0.023 -0.00035 0.0088 0.4417 0.0047 44.1675 
  20 0.42 0.023 -0.00035 0.0095 0.4757 0.0035 47.5650 
  25 0.458 0.023 -0.00035 0.0104 0.5187 0.0017 51.8685 
  30 0.47 0.023 -0.00035 0.0106 0.5323 0.0020 53.2275 
  35 0.499 0.023 -0.00035 0.0113 0.5651 0.0051 56.5118 
  40 0.51 0.023 -0.00035 0.0116 0.5776 0.0023 57.7575 
  45 0.523 0.023 -0.00035 0.0118 0.5923 0.0007 59.2298 
  
 















0 0.054 0.023 -0.00035 0.0012 0.0612 0.0011 6.1155 35.4683 44.6077 
5 0.279 0.023 -0.00035 0.0063 0.3160 0.0036 31.5968 
  10 0.356 0.023 -0.00035 0.0081 0.4032 0.0040 40.3170 
  15 0.401 0.023 -0.00035 0.0091 0.4541 0.0045 45.4133 
  20 0.431 0.023 -0.00035 0.0098 0.4881 0.0024 48.8108 
  25 0.461 0.023 -0.00035 0.0104 0.5221 0.0011 52.2083 
  30 0.475 0.023 -0.00035 0.0108 0.5379 0.0017 53.7938 
  35 0.5 0.023 -0.00035 0.0113 0.5663 0.0011 56.6250 
  40 0.507 0.023 -0.00035 0.0115 0.5742 0.0017 57.4178 
  45 0.524 0.023 -0.00035 0.0119 0.5934 0.0017 59.3430 
  
 















0 0.054 0.023 -0.00035 0.0012 0.0612 0.0007 6.1155 37.8104 44.4455 
5 0.284 0.023 -0.00035 0.0064 0.3216 0.0023 32.1630 
  10 0.355 0.023 -0.00035 0.0080 0.4020 0.0034 40.2038 
  15 0.396 0.023 -0.00035 0.0090 0.4485 0.0035 44.8470 
  20 0.442 0.023 -0.00035 0.0100 0.5006 0.0017 50.0565 
  25 0.458 0.023 -0.00035 0.0104 0.5187 0.0013 51.8685 
  30 0.473 0.023 -0.00035 0.0107 0.5357 0.0035 53.5673 
  35 0.501 0.023 -0.00035 0.0113 0.5674 0.0017 56.7383 
  40 0.508 0.023 -0.00035 0.0115 0.5753 0.0013 57.5310 







TABLES FOR DISSOLUTION PROFILES OF SALICYLIC ACID. 
This appendix includes all tables of Dissolution Profiles of Salicylic Acid Tablet at 
different tablet locations in detail. 
 














0 0.075 0.044 -0.002 0.0032 0.0095 7.3E-05 0.945 
5 0.232 0.044 -0.002 0.0097 0.0292 0.00112 2.923 
10 0.403 0.044 -0.002 0.0169 0.0508 0.00065 5.078 
15 0.576 0.044 -0.002 0.0242 0.0726 0.00091 7.258 
20 0.754 0.044 -0.002 0.0317 0.0950 0.00207 9.500 
25 0.943 0.044 -0.002 0.0396 0.1188 0.00084 11.882 
30 1.116 0.044 -0.002 0.0469 0.1406 0.00045 14.062 
35 1.302 0.044 -0.002 0.0547 0.1641 0.00050 16.405 
40 1.49 0.044 -0.002 0.0626 0.1877 0.00120 18.774 
45 1.685 0.044 -0.002 0.0708 0.2123 0.00032 21.231 
 
 















0 0.071 0.044 -0.002 0.0030 0.0089 0.00026 0.895 0.7176 99.9082 
5 0.234 0.044 -0.002 0.0098 0.0295 0.00095 2.948 
  10 0.404 0.044 -0.002 0.0170 0.0509 0.00093 5.090 
  15 0.57 0.044 -0.002 0.0239 0.0718 0.00095 7.182 
  20 0.745 0.044 -0.002 0.0313 0.0939 0.00052 9.387 
  25 0.939 0.044 -0.002 0.0394 0.1183 0.00041 11.831 
  30 1.106 0.044 -0.002 0.0465 0.1394 0.00044 13.936 
  35 1.294 0.044 -0.002 0.0543 0.1630 0.00088 16.304 
  40 1.482 0.044 -0.002 0.0622 0.1867 0.00044 18.673 
























0 0.076 0.044 -0.002 0.0032 0.0096 0.00015 0.958 25.9264 73.9092 
5 0.322 0.044 -0.002 0.0135 0.0406 0.00025 4.057 
  10 0.513 0.044 -0.002 0.0215 0.0646 0.00032 6.464 
  15 0.745 0.044 -0.002 0.0313 0.0939 0.00019 9.387 
  20 0.985 0.044 -0.002 0.0414 0.1241 0.00050 12.411 
  25 1.177 0.044 -0.002 0.0494 0.1483 0.00033 14.830 
  30 1.401 0.044 -0.002 0.0588 0.1765 0.00033 17.653 
  35 1.64 0.044 -0.002 0.0689 0.2066 0.00019 20.664 
  40 1.831 0.044 -0.002 0.0769 0.2307 0.00033 23.071 
  45 2.091 0.044 -0.002 0.0878 0.2635 0.00026 26.347 
  
 















0 0.076 0.044 -0.002 0.0032 0.0096 0.00013 0.958 35.8311 66.7539 
5 0.305 0.044 -0.002 0.0128 0.0384 0.00038 3.843 
  10 0.546 0.044 -0.002 0.0229 0.0688 0.00048 6.880 
  15 0.781 0.044 -0.002 0.0328 0.0984 0.00038 9.841 
  20 1.042 0.044 -0.002 0.0438 0.1313 0.00029 13.129 
  25 1.268 0.044 -0.002 0.0533 0.1598 0.00026 15.977 
  30 1.524 0.044 -0.002 0.0640 0.1920 0.00019 19.202 
  35 1.801 0.044 -0.002 0.0756 0.2269 0.00045 22.693 
  40 2.022 0.044 -0.002 0.0849 0.2548 0.00025 25.477 
  45 2.258 0.044 -0.002 0.0948 0.2845 0.00026 28.451 
  
 















0 0.072 0.044 -0.002 0.0030 0.0091 0.00015 0.907 36.0075 66.7063 
5 0.331 0.044 -0.002 0.0139 0.0417 0.00048 4.171 
  10 0.547 0.044 -0.002 0.0230 0.0689 0.00033 6.892 
  15 0.769 0.044 -0.002 0.0323 0.0969 0.00013 9.689 
  20 1.028 0.044 -0.002 0.0432 0.1295 0.00026 12.953 
  25 1.271 0.044 -0.002 0.0534 0.1601 0.00038 16.015 
  30 1.526 0.044 -0.002 0.0641 0.1923 0.00013 19.228 
  35 1.801 0.044 -0.002 0.0756 0.2269 0.00033 22.693 
  40 2.024 0.044 -0.002 0.0850 0.2550 0.00041 25.502 






















0 0.075 0.044 -0.002 0.0032 0.0095 0.00007 0.945 36.2310 66.6508 
5 0.341 0.044 -0.002 0.0143 0.0430 0.00044 4.297 
  10 0.548 0.044 -0.002 0.0230 0.0690 0.00048 6.905 
  15 0.774 0.044 -0.002 0.0325 0.0975 0.00084 9.752 
  20 1.032 0.044 -0.002 0.0433 0.1300 0.00067 13.003 
  25 1.267 0.044 -0.002 0.0532 0.1596 0.00086 15.964 
  30 1.526 0.044 -0.002 0.0641 0.1923 0.00100 19.228 
  35 1.804 0.044 -0.002 0.0758 0.2273 0.00051 22.730 
  40 2.024 0.044 -0.002 0.0850 0.2550 0.00038 25.502 
  45 2.265 0.044 -0.002 0.0951 0.2854 0.00026 28.539 
  
 















0 0.078 0.044 -0.002 0.0033 0.0098 0.00013 0.983 45.7711 62.1771 
5 0.351 0.044 -0.002 0.0147 0.0442 0.00038 4.423 
  10 0.63 0.044 -0.002 0.0265 0.0794 0.00025 7.938 
  15 0.925 0.044 -0.002 0.0389 0.1166 0.00015 11.655 
  20 1.106 0.044 -0.002 0.0465 0.1394 0.00038 13.936 
  25 1.325 0.044 -0.002 0.0557 0.1670 0.00032 16.695 
  30 1.623 0.044 -0.002 0.0682 0.2045 0.00032 20.450 
  35 1.956 0.044 -0.002 0.0822 0.2465 0.00025 24.646 
  40 2.158 0.044 -0.002 0.0906 0.2719 0.00033 27.191 
  45 2.318 0.044 -0.002 0.0974 0.2921 0.00032 29.207 
  
  















0 0.074 0.044 -0.002 0.0031 0.0093 0.00013 0.932 55.4641 58.0936 
5 0.356 0.044 -0.002 0.0150 0.0449 0.00133 4.486 
  10 0.639 0.044 -0.002 0.0268 0.0805 0.00122 8.051 
  15 0.943 0.044 -0.002 0.0396 0.1188 0.00079 11.882 
  20 1.247 0.044 -0.002 0.0524 0.1571 0.00081 15.712 
  25 1.512 0.044 -0.002 0.0635 0.1905 0.00079 19.051 
  30 1.772 0.044 -0.002 0.0744 0.2233 0.00084 22.327 
  35 2 0.044 -0.002 0.0840 0.2520 0.00596 25.200 
  40 2.265 0.044 -0.002 0.0951 0.2854 0.00063 28.539 
  45 2.482 0.044 -0.002 0.1042 0.3127 0.00088 31.273 
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